Wed, Oct 22, 2014, 4:04 AM EDT - U.S. Markets open in 5 hrs 26 mins

Recent

% | $
Quotes you view appear here for quick access.

Solazyme, Inc. Message Board

  • greenguru58@rocketmail.com greenguru58 Mar 1, 2013 11:03 AM Flag

    New Article: WS's Avg PT On SZYM Indicates A 56% Upside Is Expected

    New article out on InsiderMonkey.

    Solazyme Inc (NASDAQ:SZYM) saw the hedge fund hold its stake steady last quarter, as the renewable oil production player has had a solid 2013, returning just over 11%. Though shares trade at a trailing P/E north of 40x, the sell-side expects EPS to grow by 113.4% next year, with long-range estimates predicting 35% annual growth through at least 2017. Clearly, we can see what the crux of Solazyme's bullish thesis is, and it's worth noting that Wall Street's average price target on the stock indicates that a whopping 56% upside is expected from current levels. Ken Griffin (check out Griffin and Citadel's newest equity investments) and Steven Cohen were upping their stakes last quarter, giving BlueCrest some solid company.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • greenguru58@rocketmail.com greenguru58 Mar 1, 2013 11:03 AM Flag

      Full Article: Some investors view hedge funds as slow, underperforming financial vehicles of yesteryear, which is a grave misconception. For those who have known where to look, there have been ways to beat the market by focusing on the best picks of the best fund managers. At Insider Monkey, we track 450 of the industry's 8,000-plus funds, and our small-cap strategy beat the market by 18% a year for more than a decade in our back tests. Since we started sharing this strategy with the public, it has returned another 18% in just 5 months (learn how to use this yourself).

      With this in mind, it's also important to take a look at the top stock picks of each fund individually, so let's focus on Michael Platt and William Reeves's BlueCrest Capital Management. We'll look at what BlueCrest's top five equity holdings were at the end of the fourth quarter, to see how it was preparing for 2013.

      Just a quick note before we get started: it's tempting to think that the delay in hedgies' 13F filings make it impossible to track them, but in fact, just the opposite is true. Our research shows that this lag has actually aided outperformance, because on average, the smart money is early into its investments.

      Solazyme Inc (NASDAQ:SZYM) saw the hedge fund hold its stake steady last quarter, as the renewable oil production player has had a solid 2013, returning just over 11%. Though shares trade at a trailing P/E north of 40x, the sell-side expects EPS to grow by 113.4% next year, with long-range estimates predicting 35% annual growth through at least 2017. Clearly, we can see what the crux of Solazyme's bullish thesis is, and it's worth noting that Wall Street's average price target on the stock indicates that a whopping 56% upside is expected from current levels. Ken Griffin (check out Griffin and Citadel's newest equity investments) and Steven Cohen were upping their stakes last quarter, giving BlueCrest some solid company.

 
SZYM
6.71+0.30(+4.68%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.